Spotlight on Nociceptin/Orphanin FQ Receptor in the Treatment of Pain

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2022 Feb 15

PMID 35163856

Authors

Amal El Daibani

Tao Che

Affiliations

Soon will be listed here.

Abstract

In our society today, pain has become a main source of strain on most individuals. It is crucial to develop novel treatments against pain while focusing on decreasing their adverse effects. Throughout the extent of development for new pain therapies, the nociceptin/orphanin FQ receptor (NOP receptor) has appeared to be an encouraging focal point. Concentrating on NOP receptor to treat chronic pain with limited range of unwanted effects serves as a suitable alternative to prototypical opioid morphine that could potentially lead to life-threatening effects caused by respiratory depression in overdose, as well as generate abuse and addiction. In addition to these harmful effects, the uprising opioid epidemic is responsible for becoming one of the most disastrous public health issues in the US. In this article, the contributing molecular and cellular structure in controlling the cellular trafficking of NOP receptor and studies that support the role of NOP receptor and its ligands in pain management are reviewed.

Citing Articles

Effects of Opioids in Cancer Pain: An Interplay Among Genetic Factors, Immune Response, and Clinical Outcomes-A Scoping Review.

Adamczyk K, Zuzda K, Jankowski M, Swierczynski R, Chudzinski K, Czapski B Cancers (Basel). 2025; 17(5).

PMID: 40075716 PMC: 11899605. DOI: 10.3390/cancers17050863.

Nuclear Factor-κB Signaling Regulates the Nociceptin Receptor but Not Nociceptin Itself.

Zhang L, Stamer U, Moolan-Vadackumchery R, Stuber F Cells. 2025; 13(24.

PMID: 39768201 PMC: 11674636. DOI: 10.3390/cells13242111.

A genome-wide association study of European advanced cancer patients treated with opioids identifies regulatory variants on chromosome 20 associated with pain intensity.

Minnai F, Shkodra M, Noci S, Esposito M, Brunelli C, Pigni A Eur J Pain. 2024; 29(1):e4764.

PMID: 39629963 PMC: 11616469. DOI: 10.1002/ejp.4764.

The μ-opioid receptor differentiates two distinct human nociceptive populations relevant to clinical pain.

Staedtler E, Sapio M, King D, Maric D, Ghetti A, Mannes A Cell Rep Med. 2024; 5(10):101788.

PMID: 39413733 PMC: 11513826. DOI: 10.1016/j.xcrm.2024.101788.

Emerging pharmacological targets for alcohol use disorder.

Brockway D, Crowley N Alcohol. 2024; 121:103-114.

PMID: 39069210 PMC: 11638729. DOI: 10.1016/j.alcohol.2024.07.007.

References

Mollereau C, SIMONS M, Soularue P, Liners F, Vassart G, Meunier J . Structure, tissue distribution, and chromosomal localization of the prepronociceptin gene. Proc Natl Acad Sci U S A. 1996; 93(16):8666-70. PMC: 38730. DOI: 10.1073/pnas.93.16.8666. View

Zhang N, Planer W, Siuda E, Zhao H, Stickler L, Chang S . Serine 363 is required for nociceptin/orphanin FQ opioid receptor (NOPR) desensitization, internalization, and arrestin signaling. J Biol Chem. 2012; 287(50):42019-30. PMC: 3516748. DOI: 10.1074/jbc.M112.405696. View

Peluso J, LaForge K, Matthes H, Kreek M, Kieffer B, Gaveriaux-Ruff C . Distribution of nociceptin/orphanin FQ receptor transcript in human central nervous system and immune cells. J Neuroimmunol. 1998; 81(1-2):184-92. DOI: 10.1016/s0165-5728(97)00178-1. View

Daga P, Zaveri N . Homology modeling and molecular dynamics simulations of the active state of the nociceptin receptor reveal new insights into agonist binding and activation. Proteins. 2012; 80(8):1948-61. PMC: 3393802. DOI: 10.1002/prot.24077. View

Mittal N, Roberts K, Pal K, Bentolila L, Fultz E, Minasyan A . Select G-protein-coupled receptors modulate agonist-induced signaling via a ROCK, LIMK, and β-arrestin 1 pathway. Cell Rep. 2013; 5(4):1010-21. PMC: 3870884. DOI: 10.1016/j.celrep.2013.10.015. View

Neal Jr C, Mansour A, Reinscheid R, Nothacker H, Civelli O, Akil H . Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with (125)I-[(14)Tyr]-orphanin FQ binding. J Comp Neurol. 1999; 412(4):563-605. View

Hao X, Wang Z, Chen J, Wu N, Li J . Involvement of the nociceptin opioid peptide receptor in morphine-induced antinociception, tolerance and physical dependence in female mice. Metab Brain Dis. 2021; 36(8):2243-2253. DOI: 10.1007/s11011-021-00783-8. View

Khademi H, Kamangar F, Brennan P, Malekzadeh R . Opioid Therapy and its Side Effects: A Review. Arch Iran Med. 2016; 19(12):870-876. DOI: 0161912/AIM.0010. View

Ferrari F, Malfacini D, Journigan B, Bird M, Trapella C, Guerrini R . In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403. Pharmacol Res Perspect. 2017; 5(4). PMC: 5684865. DOI: 10.1002/prp2.333. View

10.

Wu Q, Liu L . ORL Activation Mediates a Novel ORL Receptor Agonist SCH221510 Analgesia in Neuropathic Pain in Rats. J Mol Neurosci. 2018; 66(1):10-16. DOI: 10.1007/s12031-018-1140-0. View

11.

Mann A, Mouledous L, Froment C, ONeill P, Dasgupta P, Gunther T . Agonist-selective NOP receptor phosphorylation correlates in vitro and in vivo and reveals differential post-activation signaling by chemically diverse agonists. Sci Signal. 2019; 12(574). PMC: 6934085. DOI: 10.1126/scisignal.aau8072. View

12.

Ding H, Hayashida K, Suto T, Sukhtankar D, Kimura M, Mendenhall V . Supraspinal actions of nociceptin/orphanin FQ, morphine and substance P in regulating pain and itch in non-human primates. Br J Pharmacol. 2015; 172(13):3302-12. PMC: 4500367. DOI: 10.1111/bph.13124. View

13.

Calo G, Rizzi A, Rizzi D, Bigoni R, Guerrini R, Marzola G . [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol. 2002; 136(2):303-11. PMC: 1573345. DOI: 10.1038/sj.bjp.0704706. View

14.

Calo G, Guerrini R, Bigoni R, Rizzi A, Marzola G, Okawa H . Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist. Br J Pharmacol. 2000; 129(6):1183-93. PMC: 1571948. DOI: 10.1038/sj.bjp.0703169. View

15.

Brownstein M . A brief history of opiates, opioid peptides, and opioid receptors. Proc Natl Acad Sci U S A. 1993; 90(12):5391-3. PMC: 46725. DOI: 10.1073/pnas.90.12.5391. View

16.

Childers S, Creese I, Snowman A, Synder S . Opiate receptor binding affected differentially by opiates and opioid peptides. Eur J Pharmacol. 1979; 55(1):11-8. DOI: 10.1016/0014-2999(79)90142-0. View

17.

Meunier J, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P . Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature. 1995; 377(6549):532-5. DOI: 10.1038/377532a0. View

18.

Wichmann J, Adam G, Rover S, Cesura A, Dautzenberg F, Jenck F . 8-acenaphthen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as orphanin FQ receptor agonists. Bioorg Med Chem Lett. 1999; 9(16):2343-8. DOI: 10.1016/s0960-894x(99)00385-6. View

19.

Ferguson S . Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev. 2001; 53(1):1-24. View

20.

Che T, Roth B . Structural Insights Accelerate the Discovery of Opioid Alternatives. Annu Rev Biochem. 2021; 90:739-761. DOI: 10.1146/annurev-biochem-061620-044044. View